Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

(Reuters) – Gilead Sciences Inc on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for the current year.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *